The purpose of this systematic review and meta-analysis was to explore the literature and collate data comparing the mortality of coronavirus disease 2019 (COVID-19) patients with and without asthma. The databases PubMed, Scopus, Embase, Google Scholar, and medRxiv.org were searched for studies comparing the clinical outcomes of asthmatic patients with those of nonasthmatic patients diagnosed with COVID-19. Mortality data were summarized using the Mantel-Haenszel OR with 95% CI in a random-effects model. Five retrospective studies met the inclusion criteria. A meta-analysis of data from 744 asthmatic patients and 8,151 nonasthmatic patients indicated that the presence of asthma had no significant effect on mortality (OR = 0.96; 95% CI 0.70–1.30; I² = 0%; p = 0.79). Results were stable in a sensitivity analysis. A descriptive analysis of other clinical outcomes indicated no difference in the duration of hospitalization and the risk of intensive care unit (ICU) transfer between asthmatic and nonasthmatic patients. To conclude, preliminary data indicates that asthma as a comorbidity may not increase the mortality of COVID-19. Data on the influence of asthma on the risk of hospitalization, the duration of hospitalization, the requirement of ICU admission, and disease severity is still too limited to draw any strong conclusions. Further studies with a larger sample size are required to establish strong evidence.
Int Arch Allergy Immunol

中文翻译：

---

哮喘会增加 COVID-19 患者的死亡率吗？：系统评价和荟萃分析。

本次系统评价和荟萃分析的目的是探索文献并整理数据，比较患有和不患有哮喘的 2019 年冠状病毒病 (COVID-19) 患者的死亡率。在数据库 PubMed、Scopus、Embase、Google Scholar 和 medRxiv.org 中搜索了比较哮喘患者与诊断为 COVID-19 的非哮喘患者的临床结果的研究。使用 Mantel-Haenszel OR 在随机效应模型中以 95% CI 总结死亡率数据。五项回顾性研究符合纳入标准。对 744 名哮喘患者和 8,151 名非哮喘患者数据的荟萃分析表明，哮喘的存在对死亡率没有显着影响（OR = 0.96；95% CI 0.70–1.30；I ² = 0%；p = 0.79）。敏感性分析结果稳定。对其他临床结果的描述性分析表明，哮喘患者和非哮喘患者的住院时间和重症监护病房 (ICU) 转移风险没有差异。总之，初步数据表明哮喘作为一种合并症可能不会增加 COVID-19 的死亡率。关于哮喘对住院风险、住院时间、入住 ICU 的要求以及疾病严重程度的影响的数据仍然有限，无法得出任何强有力的结论。需要更大样本量的进一步研究来建立强有力的证据。
Int Arch 过敏免疫